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Abstract  Superior  vena  cava  syndrome  (SVCS)  groups  all  the  signs  secondary  to  the  obstruc-
tion of  superior  vena  cava  drainage  and  the  increase  in  the  venous  pressure  in  the  territories
upstream.  There  are  two  major  causes  of  SVCS:  malignant,  dominated  by  bronchopulmonary
cancer,  and  benign,  often  secondary  to  the  presence  of  poorly  positioned  implantable  venous
devices. CT  scan  is  the  key  examination  for  the  exploration  of  SVCS.  It  speciﬁes  the  char-
acteristics of  the  stenosis,  its  aetiology  and  detects  collateral  venous  routes.  ScannographyCentral  catheter reconstructions  provide  a  true  map  of  the  obstacle,  indispensable  in  planning  the  endovascular
treatment.
© 2012  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
SVCS  groups  all  the  signs  secondary  to  the  obstruction  of  SVC  and  the  increase  in  the  venous
pressure  in  the  territories  upstream.  Malignant  aetiologies  are  most  common  (74  to  95%
of  the  cases)  (Fig.  1),  dominated  by  bronchopulmonary  cancer  (85%  of  the  cases)  [1,2].
It  most  often  consists  of  small  cell  cancers  [3].  The  lymphomas  are  the  second  leading
malignant  aetiology  (about  12%  of  the  cases)  [1].  Benign  aetiologies  are  less  common  (3  to
20%  of  the  cases)  [1].  It  often  involves  a  thrombus  around  a  central  catheter,  much  more
Abbreviations: SVCS, Superior Vena Cava Syndrome; SVC, Superior Vena Cava; IVC, Inferior Vena Cava; MIP,
Maximum Intensity Projection; ITV, Internal Thoracic Vein.
∗ Corresponding author.
E-mail address: elhajjam.mostafa@wanadoo.fr (M. El Hajjam).
2211-5684/$ — see front matter © 2012 Éditions françaises de radiologie. Published by Elsevier Masson SAS. All rights reserved.
doi:10.1016/j.diii.2012.03.025
570  A.  Lacout  et  al.
Figure 1. Bronchopulmonary tumour responsible for a superior
vena cava syndrome. The CT scan (coronal reconstruction) detects
the tumoral mass (tip of arrow) provoking a focal occlusion of the
superior vena cava (SVC) (arrow). The underlying SVC (wide arrow)
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Figure 2. Poorly positioned central catheter responsible for an
iatrogenic superior vena cava syndrome. Front chest X-ray showing
the overly short distal catheter (white arrow) and the dilation of the
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other  hand.  The  other  favouring  factors  are  represented  bys permeable and opaciﬁed by the collateral veins (re-entry by the
zygos vein). Stasis of the contrast product in the SVC underlying
he obstacle.
arely  around  the  wires  of  a  pacemaker  [4,5]. This  thrombo-
is  is  favoured  by  the  overly  short  positioning  of  the  catheter
n  the  SVC  (Figs.  2—4)  [4,6—8]. A  central  catheter  is  in  nor-
al  position  when  the  distal  end  is  located  at  the  entranceo  the  right  atrium.  An  overly  short  catheter,  whose  distal
nd  is  located  opposite  venous  convergences  leading  into  the
rch  of  the  azygos  vein  at  the  convergence  of  the  innominate
igure 3. Indirect azygos venous shunts (superior vena cava [SVC]-in
yndrome secondary to a poorly positioned catheter (too short). The diagr
ein. The latter drains in the bronchial, oesophageal and diaphragmati
etween the bronchial and the pulmonary veins and between the oesoph
t
o
orch of the azygos vein (venous shunt) indicating the obstruction of
he superior vena cava.
eins  (formerly  called  brachiocephalic  veins),  may  come  up
gainst  the  vein  walls  and  induce  endothelial  lesions  by
echanical  friction  on  the  one  hand,  or  may  provoke  rheo-
ogical  modiﬁcations  in  these  zones  of  ﬂow  turbulence  on  theferior vena cava [IVC] anastomoses) during a superior vena cava
am and the scan demonstrate the shunting by the pericardo-phrenic
c veins that then join the azygos system. There are anastomoses
agial/diaphragmatic veins and the portal system.
he  hypercoagulability  of  the  cancer  patient  and  the  toxicity
f  the  chemotherapy  products  injected  by  catheter  [4].  The
ther  benign  causes  of  SVCS  are  rarer.  It  most  often  consists
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Figure 4. Superior vena cava syndrome in a patient presenting a poorly positioned catheter. a: scan with injection, frontal reconstruction
revealing an overly short catheter, responsible for thrombosis with partial obstruction of the superior vena cava (SVC) (arrow). b: insertion
of an endoprosthesis in the SVC. c: enhanced CT scan (coronal section in maximum intensity projection [MIP]) revealing the good position
of the prosthesis and its permeability (wide arrow).
Figure 5. Hugues Stovin syndrome. Superior vena cava syndrome during Behcet’s disease. Presence of pulmonary arterial aneurisms. Tight
stenosis of the right innominate vein and the sub-azygos superior vena cava (tip of arrow). Spinal shunting (wide arrow) draining in the
superior intercostal veins, then in the arch of the large azygos vein (white arrows) to join the sub-azygos superior vena cava (black arrows).
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Figure 6. Doppler ultrasound monitoring of a superior vena
cava syndrome. Para-sternal sagittal ultrasound plane. The Doppler
ultrasound helps determine the direction of the ﬂow in the inter-
nal thoracic vein (ITV). A reverse ﬂow from the top to the bottom
(arrow) promotes a superior vena cava obstruction. The ITV sup-
plies a dilated anterior intercostal vein that is also counter-current.
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Table  1  Kishi  score  [26]. The  Kishi  score  is  used  to
quantify  the  clinical  gravity  of  the  superior  vena  cava
syndrome.  A  score  exceeding  4  is  an  indication  for  the
insertion  of  a  superior  vena  cava  endoprosthesis  by  per-
cutaneous  route.
Clinical  signs Weighting
Neurological  signs
Awareness  disorders,  coma  4
Visual  disorders,  headache,  vertigo,
memory  disorders
3
Mental  disorders 2
Malaise 1
Thoracic/pharyngeal-laryngeal  signs
Orthopnoea,  laryngeal  oedema 3
Stridor,  dysphagia,  dyspnoea  2
Coughing,  pleuresy 1
Facial  signs
Lip  oedema,  nasal  obstruction,
epistaxis
2
Facial  oedema 1
Vessel  dilation  (neck,  face,  arms)  1
Table  2  CT  classiﬁcation  of  superior  vena  cava  syn-
drome  according  to  Qanadli  [15]. It  is  used  to  quantify
the  degree  of  venous  obstruction  during  a  superior  vena
cava  syndrome.
Stage  I  Stenosis  <  90%  of  the  superior  vena  cava
Stage  II  90  to  99%  stenosis  of  the  superior  vena  cava
Stage  III  Occlusion  of  the  superior  vena  cava
Stage  IV  Occlusion  of  the  superior  vena  cava  and  one
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Vhe Dopper ultrasound may attest to the efﬁcacy of the percuta-
eous treatment by demonstrating the reappearance of a normally
irected venous ﬂow.
f  extrinsic  compressions:  mediastinal  haematoma,  benign
umours  (diving  goitre,  bronchogenic  cyst,  teratoma),  acute
r  chronic  mediastinitis,  cardiovascular  causes  (aortic  dis-
ection  or  aneurism,  constrictive  pericarditis,  pericardial
ffusion,  atrial  myxoma,  etc.).  Behcet’s  disease  may  be
esponsible  for  thrombosis  of  the  SVC  and,  when  associated
ith  pulmonary  arterial  aneurism,  give  rise  to  Hughes  Stovin
yndrome  [9,10]  (Fig.  5).
maging
he  thoracic  radiography  may  show  signs  of  the  develop-
ent  of  collateral  circulation:  opacity  above  the  right  stem
ronchus  related  to  a  dilation  of  the  arch  of  the  azygos,
ub-aortic  opacity  or  ‘‘aortic  nipple’’  corresponding  to  the
ilation  of  the  left  superior  intercostal  vein  [11]  (Fig.  2).
he  radiography  may  indicate  the  aetiology  of  SVCS:  for
xample,  tumoral  mass  or  implantable  venous  device  with  a
hort  catheter  [2].  The  SVC  permeability  may  be  evaluated
y  the  analysis  of  four  Doppler  spectra  of  the  subclavian
nd  internal  jugular  veins  [12]. The  reversal  of  the  ﬂow  of
he  collateral  veins  attests  to  the  steal  syndrome  of  the
VC:  the  ITV  has  the  same  Doppler  colour  as  its  satellite
rtery  (Fig.  6)  [13]. The  elimination  of  these  anomalies  is
sed  to  assess  the  efﬁcacy  of  the  treatment,  in  particular
ndovascular,  of  the  SVCS.  The  scan  is  the  key  examination
n  the  diagnosis  and  therapeutic  strategy.  The  MRI  may  be  an
lternative,  although  this  is  a  long  examination,  difﬁcult  to
se  in  often  dyspnoeic  patients  not  able  to  bear  the  dorsal
ecubitus  position.
The  phleboscanner  speciﬁes  the  characteristics  of  the
VC  obstruction  and  its  aetiology:  impairment  of  the  vein
all  (post-radiation  stenosis,  friction  of  an  overly  short
entral  catheter),  extrinsic  compression  (adenomegalies,
eighbouring  tumour)  and  cruoric  thrombosis  (venous  sta-
is,  hypercoagulability).  In  our  practice,  the  optimum  study
f  the  SVC  requires  a  thoraco-abdomino-pelvic  acquisition
I
o
sor  several  of  its  tributaries
0  seconds  after  the  injection  of  1.5  mL/kg  of  a  non-
onic  iodine  contrast  medium  (300  to  400  mgI/mL)  at  the
ate  of  2  mL/s.  This  acquisition,  at  the  vascular  equilib-
ium  phase,  allows  for  homogenous  venous  opaciﬁcation
nd  avoids  the  false  images  of  thrombus,  generated  by
he  ﬂow  artefacts  observed  on  the  early  acquisitions.
owever,  an  early  thoraco-abdomino-pelvic  acquisition,
btained  15  seconds  after  injection,  reveals  all  of  the  venous
hunting.  This  acquisition  is  not  indispensable  in  everyday
ractice  although  it  does  allow  for  the  exhaustive  study  of
he  venous  anatomy,  the  purpose  of  this  paper.
Stanford’s  classiﬁcation,  modiﬁed  and  adapted  for  the
canner  by  Qanadli,  is  used  to  quantify  the  severity  of
he  stenosis,  establish  a  prognosis  and  plan  for  the  care,
n  particular  the  decision  to  insert  a  SVC  endoprosthesis
Tables  1  and  2)  [14,15].  The  modelling  of  the  SVC  obstruc-
ion  obtained  with  scannography  reconstructions  allows  for
he  appropriate  choice  of  prosthesis  (diameter,  mesh  length,
esh  width,  covered  prosthesis,  etc.).
enous shuntingn  case  of  occlusion  of  the  SVC,  collateral  circulation  devel-
ps  to  shunt  the  blood  ﬂow  to  the  heart.  The  azygos
ystem  is  the  most  important  venous  system  enabling  an
Radio-anatomy  of  the  superior  vena  cava  syndrome  and  therapeu
Figure 7. Cavo-caval anastomoses via the azygos veins. Diagram
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Other  shunting  to  the  pulmonary  veins  forms  a  right-leftof the direct cavo-caval shunting by the azygos system.
anastomosis  between  the  superior  and  IVC  system  (Fig.  7).
The  azygos  system  consists  of  the  large  azygos  vein,  on  the
right,  and  the  two  small  azygos  veins,  on  the  left  [16]. Two
situations  can  be  distinguished  according  to  the  topogra-
phy  of  the  occlusion,  below  or  above  the  arch  of  the  large
azygos  vein.  The  ﬁrst  situation  corresponds  to  a  SVC  occlu-
sion  located  below  the  junction  of  the  arch  of  the  azygos
vein.  Shunting  by  the  azygos  system  may  occur  directly  or
indirectly.
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Figure 8. Superior vena cava syndrome: shunting by the azygos system
part of segment IV of the liver creating an intense contrast (hot spot sig
or the hepatic veins.tic  orientations  573
With  direct  azygos  shunting,  the  blood  ﬂows  counter-
urrent  in  the  azygos  system  and  joins  the  IVC  either  by
eans  of  the  internal  roots  of  the  azygos  veins  or  by  means
f  the  ascending  lumbar  veins  and  then  the  external  iliac
eins  (Fig.  7)  [16]. The  blood  ﬂow  may  also  join  the  ITVs  by
eans  of  the  intercostal  veins  (Fig.  8).  The  ITVs  are  anas-
omosed  to  the  epigastric  and  superﬁcial  epigastric  veins
hat  join  the  IVC  system  by  means  of  the  external  iliac
eins  and  the  internal  saphenous  veins  respectively  (Fig.  9)
17].
With  indirect  azygos  shuntings,  the  blood  ﬂows  by  the
ericardo-phrenic  veins.  The  latter  communicate  through
heir  lower  part  with  the  oesophageal  veins,  the  diaphrag-
atic  veins,  the  mediastinal  veins  and  the  bronchial  veins
hat  join  the  azygos  system  and  then  the  IVC  system  (Fig.  3)
16].  The  large  and  small  azygos  veins  communicate  behind
y  the  intra-  and  extra-spinal  venous  plexuses,  allowing  for
ransverse  contralateral  shunting  (Fig.  9)  [16].
The  superﬁcial  venous  system  also  creates  a  cavo-caval
nastomosis.  It  is  possible  to  distinguish  the  anastomoses
etween  the  innominate  veins  and  the  external  iliac  veins
hrough  the  ITVs  and  the  epigastric  veins,  and  the  anasto-
oses  between  the  axillary  veins  and  the  internal  saphenous
eins  through  the  external  thoracic  veins  and  the  superﬁ-
ial  epigastric  veins  (Fig.  10)  [17]. These  parietal  veins  are
utually  anastomosed  and  may  join  the  para-umbilical  vein
Figs.  8  and  11)  [17].enous  shunt.  In  fact,  the  bronchial  veins  are  anastomosed
n  proximity  with  the  azygos  system,  and  distally  with  the
ulmonary  veins  (Fig.  3)  [16,18,19]. Direct  anastomoses
 and the superﬁcial veins. The parietal veins drain to the anterior
n). The blood is then able to drain towards the left portal branch
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Figure 9. Spinal anastomoses. These anastomoses enable the
shunting towards the contralateral side, via the intra and extra-
spinal plexuses.
Figure 10. Superﬁcial venous anastomoses. The parietal (internal
and external thoracic, epigastric and superﬁcial epigastric) veins
e
s
b
b
d
t
a
v
i
e
g
‘
Figure 11. Hepatic shunting (hot spot sign) during a superior vena
cava syndrome. Injected scan (sagittal reconstruction in maximum
intensity projection [MIP]) revealing dilated parietal veins draining
in hepatic segment IV (determining an intense enhancement) then
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tion,  supra-sternal  venous  anastomoses  develop,  allowing
for  a  transverse  contralateral  shunt  (Fig.  12).  Therefore,
clinical  SVCS  is  not  generally  observed  if  only  one  of  thensure the shunting between the inferior vena cava (IVC) and the
uperior vena cava (SVC).
etween  the  oesophageal  and  pulmonary  veins  have  also
een  described  [20].
Other  shuntings,  towards  the  portal  system,  have  been
escribed.  The  inferior  oesophageal  veins  anastomose  with
he  left  gastric  vein  [16]. The  pericardial,  diaphragmatic
nd  parietal  veins  shunt  the  blood  ﬂow  to  the  para-umbilical
eins  at  the  notch  of  the  ligamentum  teres  [17]. This  shunt-
ng  to  the  para-umbilical  vein  accounts  for  the  very  intense
nhancement  of  contrast  medium  observed  opposite  the
roove  of  the  ligamentum  teres  during  SVCS.  They  are  called
‘hot  spot  signs’’  (Figs.  8  and  11)  [21—24]. The  blood  ﬂow
F
r
Sn the hepatic veins (black arrow) and the left portal branch (white
rrow).
hen  joins  the  left  portal  branch  at  the  rex  recess  [23,24]  or
he  hepatic  veins  directly  (Figs.  8  and  11).
The  second  situation  corresponds  to  a  SVC  occlusion
ocated  above  the  junction  of  the  arch  of  the  azygos  vein
r  at  the  occlusion  of  the  innominate  vein.  In  this  situa-igure 12. Superior vena cava syndrome by occlusion of the supe-
ior vena cava (SVC) upstream from the junction of the azygos vein.
uprasternal anastomoses via the jugular and thyroid veins.
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Figure 13. Photos of a patient presenting a superior vena cava syndrome, before and after the insertion of an endoprosthesis by percuta-
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tneous route. Disappearance of the cervico-thoracic, facial oedema 
of the endoprosthesis.
innominate  veins  is  occluded.  The  anterior  jugular  veins,
leading  into  the  innominate  vein  or  the  external  jugular
veins  are  directly  or  indirectly  anastomosed  by  way  of  the
thyroid  veins.  The  thyroid  veins  also  directly  ensure  the
contralateral  shunt  of  the  blood  ﬂow  [16]. Posterior  anas-
tomoses  also  exist  by  way  of  the  vertebral  veins  and  the
spinal  plexuses  (Fig.  9)  [16]. The  blood  joins  the  supe-
rior  intercostal  veins,  the  azygos  veins  and  the  SVC  below
the  obstacle.  Moreover,  the  blood  ﬂow  can  borrow  the
pericardial-phrenic  veins  and  the  shunts  of  the  aforemen-
tioned  superﬁcial  parietal  veins  (Figs.  3  and  10).
Symptoms
The  clinical  signs  are  related  to  the  increase  in  venous  pres-
sure  upstream  from  the  SVC  obstacle  and  the  development
of  venous  shunts  (Fig.  13).  A  so-called  ‘‘pilgrim  oedema’’
of  the  upper  part  of  the  thorax  is  observed  with  ﬁlling
of  the  sub-clavicular  hollows,  oedema  of  the  front  (preco-
cious  palpebral  oedema),  cyanosis,  dilation  of  the  superﬁcial
veins  and  swelling  of  the  jugular  veins  [25]. Deep  down,  the
oedema  may  provoke  dyspnoea  and  coughing  by  tracheo-
bronchial  impairment,  dysphagia  and  dysphonia  [2,25]. At
the  maximum,  encephalic  venous  hypertension  may  provoke
a  brain  oedema  with  headache  (increased  with  anteﬂexion),
confusion,  epilepsy  and  coma  [26]. Kishi  proposed  a  score  of
the  clinical  gravity  in  which  the  dyspnoea  and  neurological
signs  are  pejorative  [26]. The  intensity  of  the  symptoma-
tology  depends  on  the  development  of  the  collaterality.
Therefore,  an  acute  SVCS  is  often  much  more  poorly  toler-
ated  than  a  chronically  evolving  vena  cava  syndrome.  In  the
latter  case,  the  collaterality  has  the  time  to  develop.  More-
over,  Stanford’s  classiﬁcation  is  also  of  prognostic  value.  In
fact  80%  of  all  patients  with  SVCS  presenting  respiratory
distress  or  neurological  signs  have  a  Stanford  type  III  or  IV
[27].
CareThe  care  is  pluridisciplinary.  The  choice  of  the  different
treatments  depends  on  the  degree  of  urgency  to  treat  the
SVCS,  the  chemosensitivity  of  the  cancer  involved,  and  the
b
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tcompartment) and the parietal venous dilations after the insertion
canner  results  [28]. As  far  as  possible,  a  treatment  should
ot  be  prescribed  before  obtaining  a  histology  [29]. Medi-
al  care,  including  a  semi-sitting  position  favours  venous
rainage.  An  effective  dose  of  anticoagulant  treatment  and
orticotherapy  are  usually  prescribed.  However,  the  efﬁcacy
f  corticotherapy  has  not  been  demonstrated  [3,29].
In  case  the  histology  is  predictive  of  a  good  tumoral
esponse  (small  cell  carcinoma,  lymphoma  and  germ  cell
umours),  the  chemotherapy  may  induce  the  rapid  improve-
ent  of  the  symptoms  [28]. Similarly,  external  radiotherapy
ay  be  effective  in  2  to  3  weeks  [30,31]. However,  in  case
f  a  recurrence,  the  vena  cava  syndrome  may  be  poorly  tol-
rated  due  to  the  occlusion  of  the  collaterals,  secondary
o  post-radiation  ﬁbrosis  or  a  thrombosis.  The  association
f  radiotherapy  and  chemotherapy  has  not  demonstrated
ny  additional  efﬁcacy  [28]. However,  chemotherapy  and
rradiation  have  a  longer  delay  before  action  than  that  of
ercutaneous  radiology  procedure  and,  in  spite  of  the  good
nitial  results,  the  vena  cava  syndrome  recurs  in  10  to  32%
f  the  cases  [30]. In  the  acute  thromboses,  treatment  by
brinolysis  has  been  proposed  with  the  potential  risk  of
leeding  of  infra-clinical  cerebral  and  bronchial  metastases
32].  Bypass  surgery  with  venous  graft,  maintaining  several
ndications  in  benign  SVCS  [33]  is  advantageously  replaced  by
ndovascular  treatment  [34]. The  original  surgical  indication
uring  malignant  SVCS  is  thymoma,  before  external  irradi-
tion  and  after  adjuvant  chemotherapy  [35]. The  second
ndication  is  thyroid  cancer.  In  this  case,  a  triple  treat-
ent  associating  surgery,  external  irradiation  and  iratherapy
ncreases  patient  survival  [36,37].
First  described  in  1986,  the  insertion  of  a  SVC  endo-
rosthesis  is  currently  becoming  the  choice  treatment  for
VCS  (non  thrombotic  venous  axes  or  venous  axes  opened
y  angioplasty)  (Figs.  4  and  13)  [38]. It  may  be  associated
ith  the  other  means  of  treatment  described  above.  Several
tudies  have  demonstrated  its  rapidity  of  action,  efﬁcacy
nd  low  morbidity  [39—43]. Two  families  of  endoprostheses
an  be  distinguished:  expandable  endoprostheses  requiring
he  inﬂation  of  a  balloon  on  which  the  stent  has  previously
een  ﬁxed  and  self-expandable  endoprostheses  that  open
nder  the  effect  of  their  radial  strength  as  soon  as  their
heath  has  been  removed  [4].  The  scanner  helps  in  planning
he  insertion  of  the  endoprosthesis  [15]. In  practice,  we  use
576  
Figure 14. Overload syndrome. During the insertion of a superior
vena cava endoprosthesis, sudden and rapid return of the third com-
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[artment in the right cavities and pulmonary artery may provoke
re-capillary pulmonary hypertension and a pulmonary oedema.
elf-expandable  endoprostheses  whose  calibre  is  adapted
o  the  diameter  of  the  healthy  SVC,  as  measured  by  phle-
oscanner.  The  length  of  the  prosthesis  is  chosen  according
o  the  extent  of  the  diseased  zone  to  cover,  also  assessed
y  scanner.  Prostheses  with  a  diameter  ranging  from  14  to
6  mm  and  a  length  from  60  to  90  mm  are  most  often  used.
In  case  of  impairment  of  the  two  innominate  veins  or
heir  convergence,  unilateral  recanalisation  generally  suf-
ces  due  to  the  richness  of  the  transverse  anastomoses
44].  The  side  may  then  be  chosen  by  applying  the  concept
f  internal  jugular  dominance,  as  assessed  by  CT  scan  or
ltrasound.  The  opening  of  a  SVC  stenosis  inducing  a fast
ardiac  return  of  the  third  compartment  (oedema)  may
enerate  an  ‘‘overload  syndrome’’  with  pre-capillary  pul-
onary  hypertension  and  pulmonary  oedema  (Fig.  14)  [45].
his  complication  is  foreseen  by  the  assessment  of  the  car-
iac  function,  a  diuretic  treatment  and  screened  by  short
onitoring  in  an  intensive  care  unit.  The  permeability  of
VC  prostheses  seems  to  be  satisfactory  on  a  medium  term
asis  [46]. The  CT  scan  helps  specify  the  characteristics  of
he  stenosis  (nature,  location,  extent,  shunt  routes,  etc.)
nd  plan  for  the  insertion  of  the  endoprosthesis  [15]. In
ost-procedure,  an  anticoagulant  treatment  (heparin  and
elay  by  antivitamin  K)  is  prescribed  for  2  months.  A  phle-
oscanner  carried  out  after  1  month  is  indispensable  for  the
ssessment  of  the  tumoral  response,  the  control  of  the  per-
eability  and  prosthetic  positioning  and  the  disappearance
f  the  collaterals  (Fig.  4).  It  also  enables  the  diagnosis  of
he  complications  [47]. The  Doppler  ultrasound  remains  an
ncomplete  but  simple  way  to  assess  the  removal  of  the
bstacle  (Fig.  6).  The  medium  term  permeability  of  SVC
rostheses  seems  to  be  acquired  [46].onclusion
ediastinal  venous  radio-anatomy  may  be  easily  explored
n  the  presence  of  a  SVCS  leading  to  a  number  of  shunt
[
[A.  Lacout  et  al.
athways.  The  phleboscanner,  ﬁrst  intention  examination
hen  faced  with  a  SVCS,  speciﬁes  the  reliability  of  the
haracteristics  (location,  extent,  type,  mediastinal  environ-
ent)  of  the  obstruction  and  allows  for  the  precise  planning
f  the  endovascular  treatment.
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